- Home
- EWBC vs INCY Comparison
EWBC vs INCY Comparison
Compare EWBC & INCY Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- EWBC
- INCY
- Stock Information
- Founded
- EWBC 1998
- INCY 1991
- Country
- EWBC United States
- INCY United States
- Employees
- EWBC N/A
- INCY N/A
- Industry
- EWBC Major Banks
- INCY Biotechnology: Commercial Physical & Biological Resarch
- Sector
- EWBC Finance
- INCY Health Care
- Exchange
- EWBC Nasdaq
- INCY Nasdaq
- Market Cap
- EWBC 14.6B
- INCY 17.0B
- IPO Year
- EWBC 1999
- INCY 1993
- Fundamental
- Price
- EWBC $102.72
- INCY $105.55
- Analyst Decision
- EWBC Buy
- INCY Buy
- Analyst Count
- EWBC 12
- INCY 19
- Target Price
- EWBC $124.00
- INCY $89.19
- AVG Volume (30 Days)
- EWBC 757.1K
- INCY 2.8M
- Earning Date
- EWBC 10-21-2025
- INCY 10-28-2025
- Dividend Yield
- EWBC 2.33%
- INCY N/A
- EPS Growth
- EWBC 14.57
- INCY 3878.02
- EPS
- EWBC 9.07
- INCY 5.90
- Revenue
- EWBC $2,572,339,000.00
- INCY $4,813,105,000.00
- Revenue This Year
- EWBC $8.23
- INCY $19.33
- Revenue Next Year
- EWBC $7.40
- INCY $10.47
- P/E Ratio
- EWBC $11.34
- INCY $17.64
- Revenue Growth
- EWBC 6.63
- INCY 18.09
- 52 Week Low
- EWBC $68.27
- INCY $53.56
- 52 Week High
- EWBC $113.95
- INCY $109.28
- Technical
- Relative Strength Index (RSI)
- EWBC 49.85
- INCY 68.24
- Support Level
- EWBC $98.08
- INCY $91.16
- Resistance Level
- EWBC $107.04
- INCY $109.28
- Average True Range (ATR)
- EWBC 2.57
- INCY 4.59
- MACD
- EWBC 0.46
- INCY 0.49
- Stochastic Oscillator
- EWBC 52.51
- INCY 80.28
About EWBC East West Bancorp Inc.
East West Bancorp Inc operates in U.S. and Asia. The Bank provides range of personal and commercial banking services to individuals and businesses. In addition to offering traditional deposit products that include personal and business checking and savings accounts, money market, and time deposits, the Bank also offers foreign exchange, treasury management and wealth management services. The Bank has three operating segments, (1) Consumer and Business Banking, (2) Commercial Banking and (3) Treasury and Other. The company generates the majority of its revenue from the Commercial banking segment.
About INCY Incyte Corp.
Incyte focuses on the discovery and development of small-molecule drugs. The firm's leading drug, Jakafi, treats two types of rare blood cancer and graft versus host disease and is partnered with Novartis. Incyte's other marketed drugs include rheumatoid arthritis treatment Olumiant (licensed to Lilly), and oncology drugs Iclusig (chronic myeloid leukemia), Pemazyre (cholangiocarcinoma), Tabrecta (lung cancer), and Monjuvi (diffuse large B-cell lymphoma). The firm's first dermatology product, Opzelura, was approved in 2021 for atopic dermatitis and 2022 for vitiligo. Incyte's pipeline includes a broad array of oncology and dermatology programs.